Heart Tumor Market – Growing Trade Among Emerging Economies Opening New Opportunities

According to the American Cancer Society (ASC), lung cancers accounted for about 1% -2% of all carcinoids. Every year, about 4,000 lung carcinoid tumors cases diagnosed in the United States. Only 25% of primary cardiac tumors are malignant and of this 75 % are sarcomas.

Patients with malignant primary tumors face a poor prognosis, and the treatment provided is often not directed at cardiac involvement but rather on treating the origin of cancer or providing palliative care.

Geographically, the global heart tumor market is categorized into regions such as the Americas, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

Geographically, the Americas heart tumor market is segmented into two major regions North Americas and South America. North America represents the largest market worldwide owing to the increasing healthcare expenditure.

Europe has emerged as the second largest heart tumor market across the globe owing to the factors such as a rise in the demand for effective treatment of metastatic cancerous tumors such as lung, breast, and oesophageal cancers, high unmet needs for current treatment, and an increase in the research and development expenditure. These factors are expected to contribute to the growth of the global heart tumor market. The Asia Pacific is regarded as the fastest growing market.

The benign tumor is further categorized into myxoma, papillary heart tumors, fibromas, rhabdomyomas, angioma, and lipomas. The malignant tumors are divided into rhabdomyosarcoma, mesenchymomas, neurosarcoma